picolinic acid has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is considered as a severe global health problem affecting 30% of adults worldwide." | 3.01 | Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. ( Karimi, A; Khoshbaten, M; Kooshki, F; Maleki, V; Moradi, F; Niazkar, HR; Pourghassem Gargari, B, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kooshki, F | 2 |
| Moradi, F | 2 |
| Karimi, A | 1 |
| Niazkar, HR | 1 |
| Khoshbaten, M | 2 |
| Maleki, V | 1 |
| Pourghassem Gargari, B | 2 |
| Nokhostin, F | 1 |
| Bazyar, H | 1 |
2 trials available for picolinic acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
Topics: Adiponectin; Adult; Aged; Biomarkers; Double-Blind Method; Humans; Middle Aged; Non-alcoholic Fatty | 2021 |
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
Topics: Adult; alpha-2-HS-Glycoprotein; Biomarkers; C-Reactive Protein; Dietary Supplements; Double-Blind Me | 2021 |